Some targeted therapies, such as Bruton’s tyrosine kinase (BTK) inhibitors or immunomodulatory drugs (IMIDs), may have an “on-target, off-tumor” effect on the PCNSL tumor microenvironment (Table 2). The gene discussed is BTK; the disease is neoplasm.